Sep 18 2007, 10:26 AM EST
News source: Business Wire
Research and Markets (http://www.researchandmarkets.com/reports/c68778) has announced the addition of "Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report" to their offering.
"Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of acute lymphoblastic leukemia or leukemia or chronic lymphocytic leukemia or chronic myelogenous leukemia or acute myelogenous leukemia or hairy cell leukemia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
UPCOMING PATENT EXPIRES BY THERAPY AREA
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Legend
--Top 20 companies in late stage Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Projects
--Top 20 companies in early stage Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Projects
Full Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
For more information visit http://www.researchandmarkets.com/reports/c68778
Source: Life Science Analytics
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All